Stocktoria
OS Therapies Inc OSTX
NYSE American · XASE · stock · Pharmaceutical Preparations · website · IPO 2024-08-01
OS Therapies Inc financials (annual, from 10-K)
Bars are annual figures from 2023 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| R&D expense | $16.4M | $2.8M | $3.2M |
| Operating income | -$28.7M | -$6.8M | -$4.3M |
| Net income | -$28.8M | -$8.9M | -$7.8M |
| EPS (diluted) | $-0.98 | $-1.28 | $-1.46 |
| Operating cash flow | -$14.2M | -$7.3M | -$3.0M |
| Total assets | $6.8M | $5.5M | $798,082 |
| Total liabilities | $11.9M | $4.7M | $24.8M |
| Shareholders' equity | -$6.1M | -$3.3M | -$24.0M |
Source: SEC EDGAR filings · CIK 0001795091 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.